|
|
 |
|
Viewing report
|
|
|
|
Anti-Migraine Drugs - Global Strategic Business Report
Global Industry Analysts, Inc., Feb 2010, Pages: 580
This report analyzes the US And European markets for Anti-Migraine Drugs in US$ Million. Annual forecasts are provided for the period 2006 through 2015. A six-year historic Analysis is also provided for these markets. The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., Eisai, Inc., Eisai, Inc, Johnson & Johnson, Inc., Kowa Pharmaceuticals America, Inc., MAP Pharmaceuticals, Inc., Merck & Co., Inc., Merck & Co., Inc., Poze, Poze., Winston Pharmaceuticals, Inc., Wyeth Consumer Healthcare, Zogenix, Inc., AstraZeneca Plc, Bayer AG, Ethypharm S.A., GlaxoSmithKline Plc, Meda AB, Novartis AG, and Novartis AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Bipolar Disorder - Global Strategic Business Report
Opthalmic Pharmaceutical Drugs - Global Strategic Business Report
Antibacterial Drugs - Global Strategic Business Report
CNS Therapeutics - Global Strategic Business Report
Anti-Hypertensive Drugs - Global Strategic Business Report
Anti-Infectives - Global Strategic Business Report
DPP IV Inhibitors - Global Strategic Business Report
Rheumatoid Arthritis Therapeutics - Global Strategic Business Report
Prescription Drugs - Global Strategic Business Report
Pediatric Drugs and Vaccines - Global Strategic Business Report
|
|
|
|
